Effect of Personalized Prebiotic and Probiotic Supplements on the Symptoms of Irritable Bowel Syndrome: An Open-Label, Single-Arm, Multicenter Clinical Trial

被引:2
|
作者
Matsuura, Nozomi [1 ]
Kanayama, Masaya [1 ]
Watanabe, Yuta [1 ]
Yamada, Hirokazu [2 ,3 ]
Lili, Loukia [4 ]
Torii, Akira [5 ]
机构
[1] Kirin Holdings Co Ltd, Inst Hlth Sci, Hlth Sci Business Div, Fujisawa, Kanagawa 2518555, Japan
[2] Soiken Inc, Tokyo, Tokyo 1010052, Japan
[3] EviPRO Co Ltd, Tokyo, Tokyo 1010032, Japan
[4] Thorne HealthTech Inc, New York, NY 10019 USA
[5] Torii Med Clin, Tokyo, Tokyo 1570066, Japan
关键词
irritable bowel syndrome; personalized; microbiome; prebiotics; probiotics; PLACEBO-RESPONSE RATE; DOUBLE-BLIND; GUT MICROBIOTA; SEVERITY; LACTOBACILLUS; JAPANESE;
D O I
10.3390/nu16193333
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Background/Objectives: Prebiotics and probiotics have been reported to improve symptoms of irritable bowel syndrome (IBS). Nevertheless, the effects of prebiotics/probiotics can vary depending on the IBS subtypes. The purpose of this study was to investigate the effects of personalized prebiotic and probiotic supplements based on intestinal microbiota and IBS subtypes in patients. Methods: Patients with diarrhea-type IBS (IBS-D), constipation-type IBS (IBS-C), and mixed-type IBS (IBS-M) were enrolled (n = 40 per group; total: n = 120). Personalized prebiotic and probiotic supplements were determined according to the IBS subtypes and intestinal microbiota. The patients received supplements for 4 weeks. The primary outcome was the change in the IBS-severity scoring system from baseline to week 4. Results:The IBS-severity scoring system significantly decreased in all patients (-38.0 [95% confidence interval (CI): -53.6, -22.4]; p < 0.001), in patients with IBS-D (-44.5 [95% CI: -70.6, -18.5]; p = 0.004) and IBS-C (-51.2 [95% CI: -79.4, -22.9]; p = 0.002), but not in those with IBS-M (-20.0 [95% CI: -48.0, 8.1]; p = 0.47). In this study, no serious adverse events were observed that had a causal relationship with the intervention. Conclusions: In conclusion, personalized prebiotic and probiotic supplements selected according to individual intestinal microbiota and IBS subtype may alleviate the severity of IBS symptoms, particularly in patients with IBS-C and IBS-D.
引用
收藏
页数:16
相关论文
共 50 条
  • [21] The effect of fecal microbiota transplantation on psychiatric symptoms among patients with irritable bowel syndrome, functional diarrhea and functional constipation: An open-label observational study
    Kurokawa, Shunya
    Kishimoto, Taishiro
    Mizuno, Shinta
    Masaoka, Tatsuhiro
    Naganuma, Makoto
    Liang, Kuo-ching
    Kitazawa, Momoko
    Nakashima, Moeko
    Shindo, Chie
    Suda, Wataru
    Hattori, Masahira
    Kanai, Takanori
    Mimura, Masaru
    JOURNAL OF AFFECTIVE DISORDERS, 2018, 235 : 506 - 512
  • [22] A Multicenter, Open-Label, Single-Arm Trial of the Efficacy and Safety of Empagliflozin Treatment for Refractory Diabetes Mellitus with Insulin Resistance (EMPIRE-01)
    Hirota, Yushi
    Kakei, Yasumasa
    Imai, Junta
    Katagiri, Hideki
    Ebihara, Ken
    Wada, Jun
    Suzuki, Junichi
    Urakami, Tatsuhiko
    Omori, Takashi
    Ogawa, Wataru
    DIABETES THERAPY, 2024, 15 (02) : 533 - 545
  • [23] Psychological Predictors of Response to Open-Label Versus Double-Blind Placebo in a Randomized Controlled Trial in Irritable Bowel Syndrome
    Ballou, Sarah
    Haas, Julia W.
    Iturrino, Johanna
    Nee, Judy
    Kirsch, Irving
    Rangan, Vikram
    Cheng, Vivian
    Lembo, Anthony
    Kaptchuk, Ted J.
    Kelley, John M.
    PSYCHOSOMATIC MEDICINE, 2022, 84 (06): : 738 - 746
  • [24] Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)
    Okada, Morihito
    Kijima, Takashi
    Aoe, Keisuke
    Kato, Terufumi
    Fujimoto, Nobukazu
    Nakagawa, Kazuhiko
    Takeda, Yuichiro
    Hida, Toyoaki
    Kanai, Kuninobu
    Imamura, Fumio
    Oizumi, Satoshi
    Takahashi, Toshiaki
    Takenoyama, Mitsuhiro
    Tanaka, Hiroshi
    Hirano, Jun
    Namba, Yoshinobu
    Ohe, Yuichiro
    CLINICAL CANCER RESEARCH, 2019, 25 (18) : 5485 - 5492
  • [25] Surufatinib plus toripalimab in patients with advanced solid tumors: a single-arm, open-label, phase 1 trial
    Cao, Yanshuo
    Lu, Ming
    Sun, Yu
    Gong, Jifang
    Li, Jie
    Lu, Zhihao
    Li, Jian
    Zhang, Xiaotian
    Li, Yan
    Peng, Zhi
    Zhou, Jun
    Wang, Xicheng
    Shen, Lin
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (02) : 779 - 789
  • [26] Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial
    Fleseriu, Maria
    Pivonello, Rosario
    Elenkova, Atanaska
    Salvatori, Roberto
    Auchus, Richard J.
    Feelders, Richard A.
    Geer, Eliza B.
    Greenman, Yona
    Witek, Przemyslaw
    Cohen, Fredric
    Biller, Beverly M. K.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11) : 855 - 865
  • [27] Assessment of the Minimum Clinically Important Difference in Symptoms and Functions of Patients With Acute Schizophrenia: A Post hoc Analysis of an Open-Label, Single-Arm Multicenter Study
    Si, Tianmei
    Shi, Chuan
    Sun, Ling
    Zhang, Yilong
    Zhang, Lili
    FRONTIERS IN PSYCHIATRY, 2021, 12
  • [28] Short-term efficacy and safety of zonisamide as adjunctive treatment for refractory partial seizures: A multicenter open-label single-arm trial in Korean patients
    Heo, Kyoung
    Lee, Byung In
    Do Yi, Sang
    Cho, Yong Won
    Shin, Dong Jin
    Song, Hong Ki
    Kim, Ok Joon
    Park, Sung-Pa
    Kim, Sung Eun
    Kim, Sang Ho
    Lee, Jun Hong
    Kim, Kyu-Sik
    Lee, Se-Jin
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2012, 21 (03): : 188 - 193
  • [29] Effects of probiotic Bifidobacterium bifidum G9-1 on the gastrointestinal symptoms of patients with type 2 diabetes mellitus treated with metformin: An open-label, single-arm, exploratory research trial
    Hata, Shinnosuke
    Nakajima, Hanako
    Hashimoto, Yoshitaka
    Miyoshi, Tomoki
    Hosomi, Yukako
    Okamura, Takuro
    Majima, Saori
    Nakanishi, Naoko
    Senmaru, Takafumi
    Osaka, Takafumi
    Okada, Hiroshi
    Ushigome, Emi
    Hamaguchi, Masahide
    Asano, Mai
    Yamazaki, Masahiro
    Fukui, Michiaki
    JOURNAL OF DIABETES INVESTIGATION, 2022, 13 (03) : 489 - 500
  • [30] Efficacy and safety evaluation of low-intensity extracorporeal shock wave therapy on prostatitis-like symptoms: An open-label, single-arm trial
    Jin, Chen
    Zhang, Song
    Mo, Fan
    Zhang, Meng
    Meng, Jialin
    Bian, Zichen
    Fu, Ziyue
    Fang, Qiaozhou
    Kong, Xiangbin
    Feng, Bin
    Wang, Zhiping
    Jiang, Zhancheng
    Chen, Ming
    Zhang, Li
    Song, Zhengyao
    Hao, Zongyao
    Liang, Chaozhao
    ANDROLOGIA, 2022, 54 (01)